Establishment and verification of a prediction model based on clinical characteristics and positron emission tomography/computed tomography (PET/CT) parameters for distinguishing malignant from benign ground-glass nodules.
Lung adenocarcinoma
differential diagnosis
fluorodeoxyglucose F18
logistic models
positron emission tomography/computed tomography (PET/CT)
Journal
Quantitative imaging in medicine and surgery
ISSN: 2223-4292
Titre abrégé: Quant Imaging Med Surg
Pays: China
ID NLM: 101577942
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
3
5
2021
pubmed:
4
5
2021
medline:
4
5
2021
Statut:
ppublish
Résumé
To develop and verify a prediction model for distinguishing malignant from benign ground-glass nodules (GGNs) combined with clinical characteristics and We retrospectively analyzed 170 patients (56 males and 114 females) with GGNs who underwent PET/CT and high-resolution CT examination in our hospital from November 2011 to December 2019. The clinical and imaging data of all patients were collected, and the nodules were randomly divided into a derivation set and a validation set. For the derivation set, we used multivariate logistic regression to develop a prediction model for distinguishing benign from malignant GGNs. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of the model, and the data in the validation set were used to verify the prediction model. Among the 170 patients, 197 GGNs were confirmed via postoperative pathological examination or clinical follow-up. There were 21 patients with 27 GGNs in the benign group and 149 patients with 170 GGNs in the adenocarcinoma group. A total of five parameters, including the patient's sex, nodule location, margin, pleural indentation, and standardized uptake value (SUV) index (the ratio of nodule SUVmax to liver SUVmean), were selected to develop a prediction model for distinguishing benign from malignant GGNs. The area under the curve (AUC) of the model was 0.875 in the derivation set, with a sensitivity of 0.702 and a specificity of 0.923. The positive likelihood ratio was 9.131, and the negative likelihood ratio was 0.322. In the validation set, the AUC of the model was 0.874, which was not significantly different from the derivation set (P=0.989). This study developed and validated a prediction model based on
Sections du résumé
BACKGROUND
BACKGROUND
To develop and verify a prediction model for distinguishing malignant from benign ground-glass nodules (GGNs) combined with clinical characteristics and
METHODS
METHODS
We retrospectively analyzed 170 patients (56 males and 114 females) with GGNs who underwent PET/CT and high-resolution CT examination in our hospital from November 2011 to December 2019. The clinical and imaging data of all patients were collected, and the nodules were randomly divided into a derivation set and a validation set. For the derivation set, we used multivariate logistic regression to develop a prediction model for distinguishing benign from malignant GGNs. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of the model, and the data in the validation set were used to verify the prediction model.
RESULTS
RESULTS
Among the 170 patients, 197 GGNs were confirmed via postoperative pathological examination or clinical follow-up. There were 21 patients with 27 GGNs in the benign group and 149 patients with 170 GGNs in the adenocarcinoma group. A total of five parameters, including the patient's sex, nodule location, margin, pleural indentation, and standardized uptake value (SUV) index (the ratio of nodule SUVmax to liver SUVmean), were selected to develop a prediction model for distinguishing benign from malignant GGNs. The area under the curve (AUC) of the model was 0.875 in the derivation set, with a sensitivity of 0.702 and a specificity of 0.923. The positive likelihood ratio was 9.131, and the negative likelihood ratio was 0.322. In the validation set, the AUC of the model was 0.874, which was not significantly different from the derivation set (P=0.989).
CONCLUSIONS
CONCLUSIONS
This study developed and validated a prediction model based on
Identifiants
pubmed: 33936959
doi: 10.21037/qims-20-840
pii: qims-11-05-1710
pmc: PMC8047343
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1710-1722Informations de copyright
2021 Quantitative Imaging in Medicine and Surgery. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the International Committee of Medical Journal Editors (ICMJE) uniform disclosure form (available at http://dx.doi.org/10.21037/qims-20-840). The authors have no conflicts of interest to declare.
Références
AJR Am J Roentgenol. 2002 May;178(5):1053-7
pubmed: 11959700
Pol Arch Med Wewn. 2016 Apr 26;126(4):262-74
pubmed: 27121867
Arch Intern Med. 1997 Apr 28;157(8):849-55
pubmed: 9129544
AJR Am J Roentgenol. 2020 Feb;214(2):437-445
pubmed: 31714848
Ann Thorac Surg. 2015 Jul;100(1):288-94
pubmed: 26037540
Chest. 2007 Feb;131(2):383-8
pubmed: 17296637
Sci Transl Med. 2018 Nov 14;10(467):
pubmed: 30429355
AJR Am J Roentgenol. 2019 Nov;213(5):W236-W245
pubmed: 31361533
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747
Biomed Eng Online. 2018 Feb 7;17(1):20
pubmed: 29415726
Quant Imaging Med Surg. 2020 Feb;10(2):533-536
pubmed: 32190580
Thorac Cancer. 2018 Apr;9(4):452-458
pubmed: 29446528
Eur Respir Rev. 2016 Sep;25(141):247-58
pubmed: 27581824
Clin Radiol. 2019 Sep;74(9):692-696
pubmed: 31202569
Korean J Radiol. 2006 Jan-Mar;7(1):57-69
pubmed: 16549957
Lung Cancer. 2004 Jul;45(1):19-27
pubmed: 15196730
Eur Radiol. 2019 Feb;29(2):889-897
pubmed: 29967956
Radiology. 2017 Jul;284(1):228-243
pubmed: 28240562
Lung Cancer. 2009 May;64(2):171-8
pubmed: 18799230
Clin Nucl Med. 2020 Jan;45(1):e15-e19
pubmed: 31524673
J Thorac Dis. 2017 Apr;9(Suppl 3):S201-S207
pubmed: 28446985
Quant Imaging Med Surg. 2020 May;10(5):1008-1020
pubmed: 32489925
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Ann Thorac Surg. 2019 Jul;108(1):249-255
pubmed: 30876742
Expert Rev Proteomics. 2009 Feb;6(1):27-42
pubmed: 19210125
Chest. 2005 Oct;128(4):2490-6
pubmed: 16236914
Thorac Cancer. 2016 Jan;7(1):80-7
pubmed: 26913083
Lung Cancer. 2009 Aug;65(2):180-6
pubmed: 19155090
Expert Rev Respir Med. 2016;10(3):261-78
pubmed: 26751340
J Thorac Dis. 2016 Sep;8(9):2562-2570
pubmed: 27747010
Eur Radiol. 2015 Jan;25(1):155-62
pubmed: 25182626